

# Curriculum Vitae— Isaac Reuven Melamed, M.D.

Medical License #32130

## 1st Allergy & Clinical Research Center

*Focusing On Prevention*

7286 South Yosemite, Suite 180

Centennial, CO 80112

Phone: 303.773.9000

Fax: 303.770.1449

Pager: 303.626.0005

E-mail: [melamedi@njc.org](mailto:melamedi@njc.org)

Web: [www.1stallergyandresearch.com](http://www.1stallergyandresearch.com)



## I. PERSONAL HISTORY

**Date and Place of Birth:** August 26, 1951; Israel

**Present Position Rank:** Associate Professor / Investigator

**Military Service:** ZAHAL, Israel Defense Forces—1977–1982

**Main Address:** 1st Allergy & Clinical Research Center  
7286 South Yosemite, Suite 180  
Centennial, CO 80112  
August 2002–Present

**Satellite Sites:** 1st Allergy & Asthma Centers  
3655 East 104th Avenue, Suite C  
Thornton, CO 80233  
June 1994–Present

1st Immunology & Infusion Center  
7286 South Yosemite Street, Suite 110,  
Centennial, Colorado 80112

**Marital Status:** Married with three children

## II. EDUCATIONAL HISTORY

- 1965–1969:** “Ahad Ha’am” High School; Petah Tikva
- 1969–1975:** Hebrew University—Hadassah School of Medicine; Jerusalem
- 1975–1976:** Internship—Hebrew University; Jerusalem  
Title of Doctoral Dissertation: “*Evaluation of a New Pneumatic Method as Treatment of Post-Mastectomy Lymphedema*”; Supervisor: Dr. A. Zelikovski
- 1977–1981:** I.D.F. and Heller Institute—Military Medicine, Sheba Medical Center; Tel-Hashomer
- 1981–1986:** Residency in Pediatrics, Rokach (Hadassah) Hospital, Tel Aviv Medical Center; Tel Aviv
- 1989–1992:** Fellow in the Dept. of Pediatrics, Division of Immunology/Allergy, Hospital for Sick Children; Toronto, Canada
- 1992–1995:** Post-doctoral fellow, Department of Pediatrics, Division of Basic Sciences, National Jewish Center for Immunology and Respiratory Medicine; Denver, Colorado

### III. PROFESSIONAL POSITION

#### CLINICAL

- 1986:** Israel Board Certified Specialist in Pediatrics
- 1986:** Senior Staff Physician—Danna Children Hospital; Tel Aviv
- 1989:** Ontario license to practice medicine
- 1989–1992:** Fellow in the Dept. of Pediatrics, Division of Immunology/Allergy, Hospital for Sick Children; Toronto, Canada
- 1992:** Ohio license to practice medicine
- 1992:** Colorado license to practice medicine
- 1992:** Board Certification in Allergy/Asthma/Immunology
- 1992–1995:** Post-doctoral fellow, Department of Pediatrics, Division of Basic Sciences, National Jewish Center for Immunology and Respiratory Medicine; Denver, Colorado
- 1994–Present:** Private practice, 1st International Clinical Research Center, Englewood, CO; 1st Allergy & Asthma Center; Thornton, CO
- 2002–Present:** Clinical research, 1st International Clinical Research Center, Centennial, CO

**ACADEMIC**

- 1986:** Lecturer, Tel Aviv University Sackler School of Medicine
- 1988:** Associate Professor—Tel Aviv University
- 1989–1992:** Post-doctoral fellow in the Department of Pediatrics  
Division of Immunology/Allergy, Hospital for Sick Children;  
Toronto, Canada
- 1992–1995:** Post-doctoral fellow, Department of Pediatrics, Division of  
Basic Sciences, National Jewish Center for Immunology and  
Respiratory Medicine; Denver, Colorado
- 1995:** Assistant Professor, Department of Pediatrics, University  
of Colorado
- 1998:** Associate Professor, Department of Pediatrics, University  
of Colorado

#### IV. HONORS AND AWARDS

- 1978:** Faculty prize for doctoral dissertation, Hebrew University—Hadassah Medical School; Jerusalem
- 1990:** Tisdale award for excellence in research, Dept. of Pediatrics, University of Toronto, Hospital for Sick Children
- 1991:** Honorable certificate, The Third Canadian Annual Pediatric Fellows Research Symposium, Univ. of Manitoba
- 1993:** Research Award of the American Academy of Allergy and Immunology
- 2002:** Award of Clinical Immunology Society

#### V. PROFESSIONAL AFFILIATIONS

- 1981:** Israel Society for Clinical Pediatrics
- 1990:** American Academy of Allergy and Immunology
- 1990:** Clinical Immunology Society
- 1991:** American Association of Immunologists
- 1991:** American College of Allergy and Immunology
- 1992:** Canadian Society for Allergy and Immunology
- 1993:** American Society of Research
- 1993:** Colorado Society of Allergy
- 1994:** Colorado Medical Society
- 1998:** European Allergy Society
- 1999:** European Pediatric Immunodeficiency Society
- 2003:** European Society of Neuroimmunology
- 2005:** Fellow of the American Academy of Allergy and Immunology

## VI. PROFESSIONAL SERVICE AND COMMITTEES

- 1980:** Military—Head of the committee:  
“*Stress and the Immune System*”
- 1986:** Committee of Pediatric training—Sackler Medical School
- 1997:** The Asthma Committee by Prudential
- 1997:** The Autistic Society—research/clinical advisory
- 1998:** Aetna/Prudential Provider Advisory Committee

## VII. TEACHING ACTIVITIES

### ASSISTING OF DOCTORAL STUDENTS

- 1987:** Ron Keren—Sepsis and breast feeding; Tel Aviv University, Sackler Faculty of Medicine
- 1988:** Shifra Braz—The immune system in splenectomized patient; Tel Aviv University Sackler Faculty of Medicine
- 1986–1989:** Pediatric tutor of the New York Medical Program; Sackler Medical School
- 1995–Present:** Associate Professor at Children’s Hospital and National Jewish Hospital. Attending the Pediatric ward and teaching medical students and residents topics in Immune Deficiency/Asthma/Allergy, general pediatrics and use of IVIG
- Lecturer in the training programs of National Jewish Fellows:
- ▶ Immuno-clinical correlated-topics—Early B-cell signaling
  - ▶ Cell Biology Section; University of Colorado “*The Role of Signaling in Immunodeficiency.*”
  - ▶ Immune Deficiency clinic, teaching clinical fellows
  - ▶ Signaling defects in immune deficiency patients (currently on Wiskot Aldrich) (instruct research and clinical fellows)
  - ▶ Active in Pediatric Grand Rounds at National Jewish

## VIII. RESEARCH GRANTS, CONTRACTS AND SPECIAL GRANTS

- 1984:** Sackler Medical School Grant—The Immune System in IgA Deficiency
- 1992:** Travel grant—American College of Allergy and Immunology, for excellence in research in Allergy and Immunology
- 1993:** Travel grant—American College of Allergy and Immunology, for excellence in research in Allergy and Immunology
- 1994:** Research Award—American Academy of Allergy and Immunology, Janssen for allergic rhinitis
- 1994:** The use of oral gamma-globulin in chronic diarrhea (Gamm-Immune-Austria)
- 1994:** Travel grant—American Academy of Allergy and Immunology
- 1995:** NGF signaling—NIH AI-29704
- 1997:** Research grant by Pfizer—L0350: “*Allergic Rhinitis*”
- 1997:** Research grant—In-Site Clinical Study; Asthma study
- 1997:** Susan G. Komen Breast Cancer Foundation grant entitled “*The role of D-type cyclins in human cancer*”
- 1998:** NIH R21—“*Cdk6: mediator of cell signaling, growth and death.*”
- 1998:** United States Department of Defense grant—The role of Cdk6 in integration of cell signaling and cell cycle networks in human breast cancer cells
- 1998:** Research grant—Schering-P-9729304
- 1998:** Influenza study—pediatric patients with asthma
- 1998:** Influenza study—healthy pediatric patients
- 1999:** Treatment of asthmatic adolescents with Mometasone Furoate
- 1999:** Study on asthmatic children ages 6–47 months using Fluticasone Propionate

- 1999:** Study on asthmatic adolescents and adults in the long term use of Salmeterol
- 1999:** Enteroviral Meningitis study of Pleconaril in pediatrics
- 1999–2000:** Influenza study in healthy adolescent and adult patients
- 2000:** Pediatric and Adolescent observational study of Ciprofloxacin in patients with various infections
- 2000:** Study compared the use of Fluticasone Propionate and Montelukast Sodium in pediatric patients with mild to moderate asthma
- 2001:** Pediatric and Adolescent patients enrolled into this study in order to test the use of ciprofloxacin HCL.
- 2001:** This study tested the efficacy and safety of a rotavirus vaccine for newborns.
- 2001:** Pediatric and Adolescent patients enrolled into this study in order to evaluate the natural history and epidemiology of asthma in patients with severe asthma.
- 2001:** Pediatric patients enrolled into this study in order to test the use of salmeterol xinafoate medication.
- 2001:** Pediatric asthma study examined the efficacy and safety of an inhaled corticosteroid (budesonide) in the form of a nebulized treatment.
- 2001:** Examined the effect of an intranasal corticosteroid (budesonide) on the hypothalamic-pituitary-adrenal axis function in pediatric patients with allergic rhinitis.
- 2001:** Adolescent patients with seasonal allergy rhinitis enrolled into this study in order to compare two already approved antihistamine medications.
- 2001:** Healthy Pediatric and Adolescent patients enrolled into this meningococcal vaccine study.

- 2001:** Pediatric asthma study compared a treatment period of montelukast to a treatment period of beclomethasone on the average rate of linear growth.
- 2001:** Healthy infants enrolled into an immunization study in order to test various combination vaccines.
- 2001:** Adolescent Attention Deficit Hyperactivity Disorder patients enrolled in order to test the effectiveness of an extended-release psycho-stimulant medication.
- 2001:** Child/Adolescent Attention Deficit Hyperactivity Disorder (ADHD) patients who also suffer from Allergic Rhinitis enrolled in order to examine the correlation between ADHD and Allergic Rhinitis.
- 2001:** Pediatric (age 1-6) study evaluated the clinical efficacy of an investigational medication in the treatment of viral respiratory infections.
- 2001:** Adolescent (age 7-12) study evaluated the clinical efficacy of an investigational medication in the treatment of viral respiratory infection.
- 2001:** Patients (age 12 months to 8 years) study evaluated rates of seroconversion following a varicella vaccine in infants/children treated with asthma therapy.
- 2002:** Pediatrics (age 4-11) asthma study examined the efficacy and safety of fluticasone propionate/salmeterol xinafoate diskus to fluticasone propionate diskus.
- 2002:** Pediatrics (age 4-11) asthma study examined the efficacy and safety of an inhaled environmental safe propellant to be combined with fluticasone propionate.
- 2002:** Patient age 6 years and under, evaluated the effectiveness of an antibiotic otic solution in the treatment of mucus and pus like ear infections in children with ear tubes.

- 2002:** Subjects 1 year and older. Tested the effectiveness and safety of an antibiotics ophthalmic solution for treatment of pink eye.
- 2002:** Pediatrics (age 6-18 months) investigational influenza vaccine trial as a nasal spray administration product.
- 2002:** A study to assess the safety and efficacy of Immune Globulin Intravenous 10% in subjects >24 months of age with P.I.D.
- 2002:** Comparison study of patients (age 15 years to adult) receiving either: Fluticasone/Salmeterol Diskus Combo, Fluticasone Diskus, Salmeterol Diskus, or Oral Montelukast.
- 2002:** Patients (12–75 years) to test the effectiveness, safety, and tolerability of omalizumab.
- 2002:** Patients (age 4–11) with asthma to assess the safety and effectiveness of an inhaled steroid in the morning versus a placebo.
- 2002:** Patients (age 4–11) with asthma to assess the safety and effectiveness of an inhaled steroid in the morning versus a placebo.
- 2002:** Patients (age 6–8) to assess the effect of an inhaled steroid asthma medication on growth.
- 2002:** Patients (age 12–adults) with asthma to assess the safety and effectiveness of an inhaled steroid in the morning versus a placebo.
- 2002:** Patients (age 12–adults) with asthma to assess the safety and effectiveness of an inhaled steroid in the morning versus a placebo.
- 2002:** Toddlers (age 1–3) asthma study examining the efficacy and safety of an inhaled environmental safe propellant to be combined with fluticasone propionate.
- 2002:** Patients (age 6–11 years) to assess the efficacy of a fixed combination metered-dose inhaler product containing budesonide and formoterol.
- 2002:** Patients (age 6–15) to assess the efficacy of a fixed combination metered-dose inhaler product containing budesonide and formoterol.

- 2003:** Male patients (age 18–50) to assess the safety and efficacy of a non-steroidal oral medication for mild to moderate asthma.
- 2003:** Adolescents (age 12–18) to assess the safety and effectiveness of an already approved medication for the use in adolescents who suffer from migraines.
- 2003:** Female patients (age 18–65) to assess the safety and efficacy in the treatment of female subjects with severe diarrhea irritable bowel syndrome.
- 2003:** Patients (age 15 months) evaluating the administration of Hepatitis A vaccine for the immunization of children against hepatitis A at 15 months of age.
- 2003:** Patients (age 2 weeks) to assess the safety and immunogenicity (the body's ability to develop immunity against a disease) of an investigational formulation of a hepatitis B vaccine in healthy infants in their first 2 weeks of life.
- 2003:** Patients (age 6 months–5 years) to evaluate the clinical response at the end of therapy in infants and children who have recurrent and/ or persistent acute otitis media.
- 2003:** Patients (age 18–75 years) to test the safety and effectiveness of a new medication which is expected to reduce or diminish the inflammation of the airway in asthma patients.
- 2003:** Patients (age 2 months) to study the safety of the rotavirus vaccine and the vaccine's ability to prevent the rotavirus disease.
- 2003:** Patients (age 15–65 years) to evaluate the efficacy and safety of Nasonex vs. Placebo in patients with seasonal allergic rhinitis and concomitant asthma.
- 2004:** Patients (age 3 mo–5 yrs 11 mo) to assess the potential of Aclovate cream and ointment in children with moderate to severe atopic dermatitis.
- 2004:** Patients (age 3–35 mo) to evaluate the safety of a topical corticosteroid cream in children with atopic dermatitis.
- 2004:** Patients (age 12 years) evaluating the clinical effectiveness and long-term safety of Xolair (Omalizumab) in patients with moderate to severe asthma.

- 2004:** Patients (age 10–17 years) to evaluate the immunogenicity and safety of HSV vaccine in female subjects.
- 2004:** Patients (age 4–11 years) to compare Fluticasone Propionate/Salmeterol DISKUS vs. Fluticasone Propionate DISKUS in patients with activity-induced bronchospasm.
- 2004:** Patients (age 13–17 years) to compare the efficacy and safety of topical application treatment with oral cephalexin in patients with secondarily infected skin lesions.
- 2004:** Patients (age 18 years and above) to compare the efficacy of continuous vs intermittent Enbrel therapy in subjects with psoriasis.
- 2004:** Patients (age 12 years and older) to assess the efficacy and safety of SYMBICORT administered either fixed or adjustable vs a fixed regimen of Advair.
- 2004:** Pediatric study comparing the safety of two investigational drugs in the treatment of children with tinea capitis.
- 2004:** Phase three adolescent/adult study, evaluating the safety and efficacy of an investigational drug versus penicillin in the treatment of patients with tonsillitis and/or pharyngitis secondary to streptococcus pyogenes.
- 2004:** Phase three pediatric (3–24 mos) study comparing the effects of 2 doses of an investigational drug and placebo in the treatment of respiratory symptoms associated with respiratory syncytial virus-induced bronchiolitis.
- 2004–2005:** A clinical research study to assess the safety and efficacy of immunoglobulin intravenous 12% in patients (3–70 yrs) with P.I.D.
- 2004–2005:** A clinical research study to assess the safety and efficacy of immunoglobulin intravenous 10% in patients (3–70 yrs) with P.I.D.
- 2005:** Pediatric (2–11 yrs) study evaluating the efficacy and safety of once daily, investigational nasal spray drug in patients with seasonal allergic rhinitis.
- 2005:** Pediatric (6–11) study evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of an investigational drug in children with moderate-severe, persistent, inadequately controlled allergic asthma.

- 2005:** Pediatric (6–11 yrs) study comparing the safety and efficacy of an investigational nasal spray drug in patients with seasonal allergic rhinitis.
- 2005:** Pediatric (4–6 yrs) study to determine the safety and immunogenicity of an investigational combination vaccine, when administered as a 5th dose in this age group.
- 2005:** Phase three, pediatric (6–14 yrs) study comparing the clinical effects of an investigational intravenous drug in patients with acute asthma.
- 2005:** Adolescent (12–17) study comparing the safety and efficacy of an investigational drug in migraine prophylaxis.
- 2005:** Adult (15 and up) study comparing the clinical effects of an investigational intravenous drug in patients with acute asthma.
- 2005:** Adult (18 yrs and up) study to evaluate the relationship and impact of clinical symptoms of allergic rhinitis, on key patient reported outcomes in addition to establishing a minimally important difference in overall symptoms of allergic rhinitis, with particular regard to nasal congestion and morning allergy symptoms.
- 2005:** Adolescent (12–17) long-term study to determine the safety of an investigational study drug in the treatment of migraines.
- 2006:** Pediatric (2months) study comparing safety, tolerability and immunologic noninferiority of an investigational vaccine, in conjunction with routine pediatric vaccinations in the United States.
- 2005-2006:** A clinical research study to assess the safety, efficacy and pharmacokinetics of immunoglobulin intravenous 10% in patients (3-70 yrs) with P.I.D.
- 2006:** An extended clinical research study to assess the safety and efficacy of immunoglobulin intravenous 10% in patients (3-70 yrs) with P.I.D.
- 2006:** Adult (18 yrs and up) study comparing clinical outcomes of 2 antibiotics in patients with Community Acquired Lower Respiratory Tract Infections.

- 2006:** Pediatric (6-18 years) study of a nasal spray used for the treatment of nasal polyps.
- 2006:** Adult (18 yrs and up) study to assess the efficacy and safety study of an investigational asthma inhaler compared to formoterol TBH, budesonide pMDI & placebo in COPD patients.
- 2006:** A clinical study of the Pharmacokinetics, efficacy and safety of Immune Globulin Intravenous (Human) in patients (3-70 yrs) with P.I.D.
- 2005-2006:** Pediatric (6-<12 years) study evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of omalizumab (Xolair) in children with moderate-severe, persistent, inadequately controlled allergic asthma.
- 2005-2006:** Pediatric (6 to 14 yrs) study comparing the clinical effects of intravenous montelukast with placebo in pediatric patients (ages 6 to 14 years) with acute asthma.
- 2006:** Pediatric (6 to 14 yrs) study to evaluate the clinical effect of oral montelukast versus placebo in persistent asthma which is also active during allergy seasons in pediatric patients with seasonal aeroallergen sensitivity.
- 2005:** Pediatric (4 to 6 yrs) study evaluating the safety and immunogenicity of DAPTACEL administered as a 5th dose in children previously immunized with DAPTACEL or Pentacel.
- 2006:** Adolescent/Adult (13 yrs and up) comparative study to evaluate the efficacy and safety of an investigative antibiotic, versus penicillin V, in patients with Streptococcus pyogenes tonsillitis/pharyngitis
- 2006:** Pediatric (6 months to 13 yrs of age) comparative study to evaluate the efficacy and safety of an investigative oral suspension antibiotic versus penicillin V oral solution, in children with Streptococcus pyogenes tonsillitis/pharyngitis
- 2006:** Pediatric (6 to 14 yrs of age) A study to evaluate the efficacy and safety of chewable montelukast when initiated at the start of the school year in pediatric patients with asthma.

- 2006:** Adult (18 yrs and up) A Qualitative Study of the Cardinal Symptoms in Patients with Chronic Sinusitis
- 2006:** Adolscent (11 to 18 yrs of age) A study to evaluate the safety and immunogenicity of an investigational vaccine co-administered intramuscularly with the Boostrix vaccine and/or Menactra vaccine according to different dose schedule combinations as compared to the investigational vaccine, Boostrix or Menactra alone in healthy female subjects aged 11-18 years
- 2007:** A pediatric study to assess the systemic exposure to investigational study medication in patients with Infant Wheezing.
- 2007:** A study evaluating the effects of an investigational study drug in patients with mild to moderate asthma.
- 2007:** An open label, single arm study to assess the safety and immunogenicity of a study medication administered subcutaneously over a period of 6 months to male and female adolescents and adults with moderate to severe persistent allergic asthma.
- 2007:** An observational follow-up study of pediatric patients who participated in a previous Respiratory Syncytial Virus (RSV) – Induced Bronchiolitis study.
- 2007:** A clinical study of the pharmacokinetics, efficacy and safety of immune globulin intravenous (Human) in subjects with Primary Immune Deficiency Diseases.
- 2007:** A study evaluating the tolerability and pharmacokinetic comparison of study drug administered intravenously or subcutaneously in subjects with Primary Immunodeficiency Diseases.
- 2007:** A phase III study of the efficacy, tolerability, safety, and pharmacokinetics of immune globulin subcutaneous in subjects with Primary Immunodeficiency (PID).
- 2007:** A phase III, randomized, active-control, double-blind trial evaluating the safety, tolerability and immunogenicity of a pediatric pneumococcal vaccine in healthy infants given with routine pediatric immunizations in the United States.

- 2007:** A phase III clinical trial comparing the safety and efficacy of a combination inhaler to using the components separately or placebo in adolescent and adult patients with mild to moderate asthma.
- 2007:** A phase II clinical trial to evaluate the safety of an inhaled solution in post surgical subjects with Chronic Sinusitis.
- 2007:** A phase IIIb exacerbation clinical trial to compare the effect of two inhaled medications given twice-daily in COPD patients.
- 2007:** A study of the therapeutic equivalency of inhalers in corticosteroid-dependent subjects with moderate asthma.
- 2007:** Safety study of a meningococcal vaccine when administered with other pediatric vaccines to healthy toddlers.
- 2007:** Determination of the dose of investigational medication required enabling up to 600 mg/kg of IGIV, 10% to be administered subcutaneously in a single infusion site in patients with Primary Immunodeficiency Disease.
- 2007:** A clinical trial of evaluating a medication for C-reactive protein reduction in early treatment of Type 2 Diabetes.
- 2007:** A study to evaluate the efficacy, tolerability and safety of daily oral administration of an investigational medication in subjects with relapsing remitting (R-R) Multiple Sclerosis (MS).
- 2007:** A study evaluating the safety and efficacy of nasal spray in 6-11 year old patients with Seasonal Allergic Rhinitis.

## IX. BIBLIOGRAPHY

### PAPERS PUBLISHED IN REFERRED JOURNALS

1. A. Zelikovski, **I. Melamed**, I. Kott, M. Manoach, I. Urca: The "Lymphapress" - a new pneumatic device for the treatment of lymphedema: clinical trial and results. *Folia Angiol* 28:165-169, 1980.
2. **I. Melamed**, I. Romem: Is bicarbonate needed in shock treatment? *Harefuah* 11:397-399, 1980.
3. **I. Melamed**, Y. Romem, G. Keren, Y. Epstein and E. Dolev: March myoglobinemia - A hazard to renal function. *Arch Int Med* 142:1277-1279, 1982.
4. **I. Melamed**, V. Zakuth, E. Tzechoval and Z. Spirer: Suppressor T cell activity in splenectomized subjects. *J Clin Lab Immunol* 7:173-176, 1982.
5. **I. Melamed**, Z. Spirer: Aging and the immune system. *Harefuah* 102:31-33, 1982.
6. **I. Melamed**: March myoglobinemia. *Arch Int Med* 142:6739, 1982.
7. **I. Melamed**, Y. Bujanover, J. Hammer, Z. Spirer: Hepatoblastoma in an infant born to a mother after hormonal treatment for sterility. *N. Engl J Med* 307:820, 1982.
8. **I. Melamed**, Y. Romem, T. Shimoni, Y. Pereck and E. Dolev: Overdose of booster tetanus toxoid given in error: A clinical study. *Scand J Infec Dis* 15:303-306, 1983.
9. **I. Melamed**, Y. Bujanover, Y. Igra, D. Schwartz, V. Zakuth and Z. Spirer: campylobacter enteritis in normal and immunodeficient children. *Am J Dis Child* 137:752-753, 1983.
10. **I. Melamed**, S. Shemer, V. Zakuth, M. Pras and Z. Spirer: The immune system in FMF. *Clin Exp Immunol* 46:77-81, 1983.
11. **I. Melamed**, M. Djaldetti, H. Joshua and U. Seligson: Association of factor VIII: C deficiency and hemorrhagic thrombocytopeny with dilation of platelet membrane complex. *Acta Haematol* 71:381-387, 1984.
12. **I. Melamed**, Y. Bujanover and Z. Spirer: Neurologic complication in campylobacter jejuni enteritis. *Harefuah* 106:455, 1984.
13. **I. Melamed**, D. Chitayat, V. Zakuth and Z. Spirer: Incomplete transient immunodeficiency in children. *Harefuah* 106:350-352, 1984.

14. **I. Melamed**, A. Aviram, A. Rubinstein, V. Zakuth, G. Pereschansky and Z. Spirer: Inhibition of lymphocyte response to mitogens by dipyridamole: preliminary findings. *Eur J Clin Pharm* 28:263-265, 1985.
15. **I. Melamed**, Y. Bujanover, Y. Siegman-Igra, V. Zakuth and Z. Spirer: Campylobacter enteritis in normal and immunodeficient children. *Campylobacter* II, Ed., A.D. Pearson, M.B. Skirrow, B. Bowe, J.R. Davis, D.M. Jones, 1985.
16. **I. Melamed**, V. Zakuth, D. Schwartz and Z. Spirer: The immune response to campylobacter infection. *Campylobacter* III, Ed., A.D. Pearson, M.B. Skirrow, B. Bowe, J.R. Davis, D.M. Jones, 1987.
17. **I. Melamed**, J.D. Kark, V. Zakuth and Z. Spirer: The immune system in isolated IgA deficiency. *J Clin Lab Immunol* 17:163-166, 1985.
18. **I. Melamed**, Y. Bujanover, D. Schwartz, N. Conforty and Z. Spirer: Polymicrobial infection in campylobacter enteritis. *Br Med J* 291:633-634, 1985.
19. **I. Melamed**, S. Diamant, A. Fattal and Z. Spirer: Kawasaki disease with serologic evidence of streptococcal infection. *Infection* 14:91-92, 1986.
20. **I. Melamed**, J.D. Kark, V. Zakuth, G. Margalit and Z. Spirer: Serum immunoglobulin A levels and ethnicity in an Israeli population sample. *Clin Immunol Immunopathol* 41:5, 1986.
21. Y. Bujanover, **I. Melamed** and D. Branski: Campylobacter jejuni enteritis in normal and immunodeficient children. *Front Gastrointestinal Res* 13:343-354, 1986.
22. Z. Spirer, M. Holtzman, **I. Melamed** and I. Shalit: Age distribution of anginose mononucleosis. *Arch Dis Child* 62:617-619, 1987.
23. **I. Melamed**, Y. Bujanover, D. Schwartz, M. Rogol and Z. Spirer: Persistent campylobacteriosis in an immune deficient child. *J Diar Res* 3:186-187, 1987.
24. **I. Melamed**, V. Zakuth, D. Schwartz and Z. Spirer: The immune system response to campylobacter infection. *Microbiol Immunol* 32:75-82, 1988.
25. **I. Melamed**, S. Kabili, V. Zakuth and Z. Spirer: The immune system in FME. *J Clin Lab Immunol* 26:125-128, 1988.
26. Z. Spirer, V. Zakuth, E. Tzechoval, S. Dagan, M. Friedkin, A. Golander and **I. Melamed**: Tuftsin stimulates IL-1 production by human mononuclear cells and mouse spleen cells in vitro. *J. Clin Lab Immunol.* 28:27-31, 1989.

27. **I. Melamed:** Pneumovax vaccine: new aspects. Harefuah. 116:166-8, 1989.
28. Z. Spierer, V. Zakuth, E. Tzechoval, S. Dagan, B. Lev, A. Golander and **I. Melamed:** Decreased interleukin 1 and interleukin 2 production in splenectomized patients. J. Clin Lab Immunol. 28:372, 1989.
29. **I. Melamed**, J. Kark and Z. Spierer: Coffee and the immune system. J Immunopharm 12, 1:129-134, 1990.
30. D. Schwartz, **I. Melamed**, D. Cohen, N. Konforti and J. Goldhar: Elisa for campylobacter jejuni antibodies in Israeli children with diarrhea and in healthy soldiers. Israel J Med Sci 26:6-319-324, 1990.
31. **I. Melamed**, G. Downey and C.M. Roifman: Cytoskeletal changes associated with B cell activation. FASEB J 4, A640, 1990.
32. **I. Melamed**, S. Pheanny, P. Shermann and C.M. Roifman: Benefit of Ketotifen in eosinophilic gastroenteritis. Amer J Med 90:310-314, 1991.
33. **I. Melamed**, G.P. Downey and C.M. Roifman: Tyrosine phosphorylation is essential for microfilament assembly in B lymphocytes. Biochem and Biophys Res Commun 166, 3:1424-1429, 1991.
34. **I. Melamed**, A.M. Griffiths and C.M. Roifman: Benefit of oral immune-globulin in immune deficient children with diarrhea. J Peds, 119:486-489, 1991.
35. **I. Melamed**, G.P. Downey and C.M. Roifman: Microfilament assembly is required for antigen-receptor-mediated activation of human B lymphocytes. J Immunol 147:1139-1146, 1991.
36. **I. Melamed**, G. Wang and C.M. Roifman: Antigen-receptor-mediated protein kinase activity is regulated by a pertussis toxin sensitive G-protein. J Immunol 149:169-174, 1992.
37. **I. Melamed**, R.A. Franklin, C. Brodie, J.J. Lucas and E.W. Gelfand: Signaling of B lymphocytes by nerve growth factor: tyrosine phosphorylation of phospholipase Cg1, MAP2-Kinase and gp140trk. J Immunol 150, 8, 182A, 1993.
38. R.A. Franklin, C. Brodie, **I. Melamed**, N. Terada, J. Lucas and E.W. Gelfand: Nerve growth factor induced activation of MAP2-Kinase and P90rsk in B lymphocytes. J Immunol 150, 8, 181A, 1993.

39. **I. Melamed**, C.A. Kelleher, R.A. Franklin, C. Brodie, J.B. Hempstead, D. Kaplan and E.W. Gelfand: Signaling of B lymphocytes by nerve growth factor: gp140trk as a neuro-immune adaptor. *Molec Biol Cell* 4, 123, 1993.
40. **I. Melamed**, C. Turner and E.W. Gelfand: Nerve growth factor triggers microfilament assembly and paxillin phosphorylation in B lymphocytes. *J All Clin Immunol* 93, 285, 1994.
41. **I. Melamed**, L. Stein and C.M. Roifman: Epstein-Barr virus induces actin polymerization in human B cells. *J Immunol*, 153:1998-2003, 1994.
42. **I. Melamed**, A. Cohen and C.M. Roifman: Expansion of CD3+ CD4- CD8- T cell population expressing high levels of IL-5 in Omenn's syndrome. *Clin Exper Immunol*. 95:14-21, 1994.
43. **I. Melamed**, C.E. Turner, K. Aktories, D. Kaplan and E.W. Gelfand: Nerve growth factor (NGF) triggers microfilament assembly and paxillin phosphorylation in B lymphocytes. *J Exp Med* 181:1071-1079, 1995.
44. R.A. Franklin, C. Brodie, **I. Melamed**, N. Terada, J. Lucas and E.W. Gelfand: Nerve growth factor induces activation of MAP2-kinase and p90rsk in human B lymphocytes. *J Immunol*.154:4965-4972, 1995.
45. **I. Melamed**, R.A. Franklin and E.W. Gelfand: Microfilament assembly is required for anti-IgM dependent MAPK and p90rsk activation in human B lymphocytes. *Biochem Biophys Res Commun* 209:1102-1110, 1995.
46. **I. Melamed** and E.W.Gelfand: Modulation of activated B and T cell tyrosine phosphorylation by IVIG. *The Journal of Allergy and Clinical Immunology*, 97(1)406, 1996.
47. **I. Melamed**, C.A. Kelleher, R.A. Franklin, C. Brodie, B. Hempstead, D. Kaplan and E.W. Gelfand: Signaling of B lymphocytes by nerve growth factor gp140trk as a neuro-immune adaptor. *European Journal of Immunology*, 26:1985-1992, 1996.
48. M. Nagasawa, **I. Melamed**, A. Kupfer, E.W. Gelfand and J. Lucas: Rapid nuclear translocation and increased activity of cyclin-dependent kinase 6 after T cell activation. *J. Immunology*, 158, 5146-5154,1997.
49. **I. Melamed**, C.M. Pleiman, J.C. Cambier and E.W. Gelfand: Direct Interaction of V-src with cytoskeletal proteins in human B lymphocytes.2002, B.B.R.C (submitted).

50. **I. Melamed**, H. Patel, C. Brodie and E.W. Gelfand: Activation of Vav and Ras through the Nerve Growth Factor and B cell receptors by different kinases. *J. Cellular Immunology* 191, 83-89, 1999.
51. **I. Melamed** and E.W. Gelfand: Microfilament assembly is involved in B-cell apoptosis, *The J. of Allergy and Clinical Immunology* 103 (1) 242, 1999.
52. **I. Melamed**, C.M. Roifman and E.W. Gelfand: A new autosomal recessive skeletal dysplasia with immune deficiency and abnormal Vit. D signaling. 2000, *Clinical Immunology Journal* (submitted).
53. O. Jirapongsananuruk, **I. Melamed**, D.Y.M. Leung: Additive immunosuppressive effects of 1, 25-dihydroxyvitamin D3 and corticosteroids on TH1, but not TH2, responses. *J. Allergy and Clinical Immunology*, 106 (5) 981-985, 2000.
54. **I. Melamed**, J. Levy, S. Shatzky, R. Parvari and E.W. Gelfand: A novel immunodeficiency Trk A-Mutation in patients with congenital insensitivity to pain and anhidrosis (CIPA). *Journal of Clinical Immunology*, 24 (4) 441-448, 2004.
55. **I. Melamed** and E.W. Gelfand: The role of CD40L in the pathogenesis of autism. 2003, *NEJM*, (in preparation).
56. C. M. Roifman **I. Melamed**: A novel syndrome including combined immunodeficiency, autoimmunity and spondylometaphyseal dysplasia. *Clin Genet* 63 (6) 522-529, 2003
57. **I. Melamed**, B. Bender, M. Wamboldt: Attention deficit disorder and allergic rhinitis—are they related? The benefit of using ceterizine in children with comorbid disease: ADHD and allergy. 2004 (in preparation)
58. **I. Melamed**, B.A. Freiberg, C.M. Pleiman, J. Cambier, A. Kupfer, J.J. Lucas, E.W. Gelfand: Interaction of cyclin-dependent kinase 6 (cdk6) with the tyrosine kinase fyn as an early event In T-cell activation. 2004 (submitted).
59. S. Beard, D. Bar-Or, **I. Melamed**: Parvovirus as a cause of severe ataxia in an immune-deficient patient and the benefit of high-dose intravenous immunoglobulins. *Pediatr Allergy Immunol.* (submitted)
60. **I. Melamed**, J. DeAnna: Identifying the efficacy and safety of anti-influenza treatment for patients with pediatric asthma. (in preparation).

61. **I. Melamed** . B.G Bender, M.Z.Wamboldt; The Benefit of using Ceterizine (Zyrtec) with stimulants in children with comorbid allergy and ADHD. *J.Allergy Clin. Immunology*. 113(2) 551, 2004.
62. A. Smith, F. Accurson, **I. Melamed**: Single mutation in the cystic fibrosis transmembrane regulatory gene in patients with chronic sinusitis and hypogammaglobulinemia: A novel immunodeficiency. *J Allergy and Clinical Immunol*, 113 (2) 75, 2004.
63. S. B. Beard, **I. Melamed**: The benefit of high dose IVIG treatment in an immunocompromised patient who presented with idiopathic tremor. *Annals of Asthma and Immunology*, 2004.
64. G. Thomas, L. Rael, R. Shimonkovitz, **I. Melamed**, D. Bar-Or: Autoantibody reaction to myelin basic protein by plasma Parvovirus B19 IgG in MS patients. *Proteins*, 2005. (accepted).
65. **I. Melamed**, D. Bar-Or: Tetracyclines from antibiotics to antiseptis. *Critical Care Medicine*, 33, 7, 2005.
66. S. B. Kelly, **I.Melamed**, D.Bar-Or: Anti-Myelin Antibodies as an Immuno-modulatory Marker for IVIG Treatment in Patients with Progressive Multiple Sclerosis. *Clinical Immunology*, Sup-1 ,S93, 2005.
67. J. A. Church, H. Leibl, M. R. Stein, **I. Melamed**, A. Rubinstein, et al. Efficacy, Safety and Tolerability of a New Intravenous Immune Globulin, 10% Liquid, Triple Virus Reduced (IGIV, 10%TVR) in Patients with Primary Immunodeficiency (PID). (submitted)
68. **I. Melamed**, A. McDonald, B. Jessen: Atopy as a Cause of Delayed Maturation of the Immune System. *Clinical Immunology* 2006; 119 (S): F.21.
69. **I. Melamed**, A. McDonald, M. Gonzalez: Autism as a Neuro-immune Disease-the Benefit Effect of IVIG. *Clinical Immunology* 2006; 119 (S): Sa. 46.
70. **I. Melamed**, S. Kelley, A. McDonald, D. Bar-Or: The Immunomodulatory Effect of IVIG in Parvovirus B-19 Induced Neuroimmune Disease. *Clinical Immunology* 2006; 119 (S): Sa. 45.

71. **I. Melamed**, A. Smith, F. Accurso: The Benefit of IVIG in Children with Chronic Sinus Disease Secondary to Single Mutation in the Cystic Fibrosis Transmembrane Regulatory Gene. *Clinical Immunology* 2006; 119 (S): Sa. 107.
72. D. Bar-Or, L. Rael, R. Bar-Or, G. Thomas, D. Stone, **I. Melamed**, et. al.: Severe systemic immune response syndrome, low plasma paraoxonase activity, and a new albumin species in a traumatized patient with gaucher's disease. *Clinica Chimica Acta* (2006), doi: 10.1016/j.cca.2006.05.046.
73. M. Berger, C. Cunningham-Rundles, F. Bonilla, **I. Melamed**, J. Bichler, M. Ballow: Carimune NF Liquid is safe, effective, and well tolerated immunoglobulin replacement therapy in patients with primary immunodeficiency diseases. (pending)

**BOOKS AND REVIEWS**

1. **I. Melamed**, Y. Romem, G. Keren, Y. Epstein and E. Dolev: Myoglobinemia - A Hazard to Renal Function. 1984 Year Book of Emergency Medicine.

**OTHER PUBLICATIONS**

1. **I. Melamed** and V. Steiner: Herpes simplex labialis. I.D.F. Bulletin 1:25, 1980.
2. **I. Melamed**: Dopamine. I.D.F. Bulletin 1:29, 1980.

**PRESENTATIONS**

1. **I. Melamed**, V. Zakuth, E. Tzechoval and Z. Spirer: Suppressor T-cell activity in splenectomized subjects. Israel Ped Assoc Meeting, Herzelia, 1981.
2. **I. Melamed**, Y. Romem, G. Keren and E. Dolev: Acute exertional rhabdomyolysis in recruits. 12th World Congress of Israel Med Assoc, Jerusalem, 1982.
3. **I. Melamed**, D. Chitayat, V. Zakuth and Z. Spirer: Transient immune deficiency in children. Israel Pediatrics Assoc, Herzelia, 1982.
4. **I. Melamed**, S. Shemer, V. Zakuth, M. Pras and Z. Spirer: The immune system in FMF. Israel Ped Assoc, Tel Aviv, 1983.
5. Y. Bujanover, **I. Melamed**, Y. Siegman-Igra, V. Zakuth and Z. Spirer: Campylobacter enteritis in normal and immunodeficient children. European Soc of Ped Gastroenterol, Graz, Austria, 1983.
6. **I. Melamed**, et al: Campylobacter enteritis in immune deficient children. 2nd International Workshop of Campylobacter Infec, Brussels, Belgium, 1983.
7. **I. Melamed**, V. Zakuth, Y. Burenstein and Z. Spirer: Blastogenic response to V-Z antigen in normal and immune suppressed children. Israeli Peds Assoc, Tel Aviv, 1984.
8. **I. Melamed**: The immune response to campylobacter infection. 3rd International Workshop on Campylobacter Infec, Ottawa, Canada, 1985.
9. **I. Melamed**, J.D. Kark and Z. Spirer: Serum IgA levels in different ethnic groups. Israel Peds Assoc, Tel Aviv, 1985.

10. **I. Melamed**: The association of NEC to campylobacter infection. IVth International Workshop on Campylobacter Infect, Goeteborg, Sweden, 1987.
11. D. Schwartz and **I. Melamed**: Enzyme-linked immunosorbent assay in diagnosis of campylobacter jejuni infection in Israel children. Israel Microbiology Association, Rehovot, 1987. Abstract: Israel J of Med Sci 23:855-856, 1987.
12. **I. Melamed**, J. Kark and Z. Spirer. Coffee and the immune system. Eur Immunol Congress, Zagreb, 1987.
13. **I. Melamed**, S. Kabili and Z. Spirer: FMF and the immune system. Eur Immunol Congress, Zagreb, 1987.
14. **I. Melamed**, V. Zakuth and Z. Spirer: Decreased IL-1 and IL-2 production post splenectomy. Israel Soc of Immunol, Beer Sheva, 1988.
15. **I. Melamed**, D. Schwartz and Y. Goldharer: Campylobacter and necrotizing enterocolitis. 5th International Workshop on Campylobacter Infections. Mexico, 1988.
16. D. Schwartz, **I. Melamed**, Z. Spire, D. Cohen, N. Konforty and J. Goldhar: Elisa for c. jejuni antibodies in Israeli children and soldiers. Proceeding of the 16th International Congress of Chemotherapy, Israel, June 1989.
17. **I. Melamed**, G. Doweny and C.M. Roifman: Cytoskeletal changes associated with B cell activation, FASEB meeting, Washington DC, 1990.
18. **I. Melamed**, G. Doweny and C.M. Roifman: Mitogen induced microfilament assembly. Clin Immunol Meeting, Chicago, 1990.
19. **I. Melamed**, G.P. Downey, A. Choen and C.M. Roifman: B cell activation is dependent on vimentin, Atlanta, FASEB Meeting, 1991.
20. **I. Melamed** and C.M. Roifman: Unrelated matched bone marrow transplantation for Ommen's Syndrome. ACAI, 1992.
21. **I. Melamed**, R.A. Franklin, C. Brodie, J. Lucas and E.W. Gelfand: Signaling of B lymphocytes by nerve growth factor: tyrosine phosphorylation of phospholipase Cg1, MAP2-Kinase and GP140trk. Amer Assoc Immunol, Denver, 1993.
22. R.A. Franklin, C. Brodie, **I. Melamed**, N. Terada, J. Lucas and E.W. Gelfand: Nerve growth factor induced activation of MAP2-Kinase and P90rsk in B lymphocytes. Amer Assoc Immunol, Denver, 1993.

23. **I. Melamed**, C.A. Kelleher, R.A. Franklin, C. Brodie, J.B. Hempstead, D. Kaplan and E.W. Gelfand: Signaling of B lymphocytes by nerve growth factor: gp140trk as a neuro-immune adaptor. Cell Biol Meeting, New Orleans, 1993.
24. **I. Melamed**, C. Turner and E.W. Gelfand: Nerve growth factor (NGF) triggers microfilament assembly and paxillin phosphorylation in B lymphocytes. Amer Acad All and Immunol, 1994.
25. **I. Melamed** and E.W. Gelfand: Modulation of activated B and T cell tyrosine phosphorylation by IVIG, American Academy of Immunology, New Orleans, 1996.
26. **I. Melamed**, H. Patel and E.W. Gelfand: Trk tyrosine kinase dependent activation of Vav/Ras in human B cells by nerve growth factor, AAI meeting, San Francisco, 1997.
27. **I. Melamed**, H. Patel and E.W. Gelfand: Activation of Vav and Ras through the nerve growth factor, 5th IUBMB –The Biochemistry of Health and Diseases, Jerusalem, 1998.
28. **I. Melamed** and E.W. Gelfand: Microfilament Assembly is Involved in Apoptosis, 5th IUBMB –The Biochemistry of Health and Diseases-Jerusalem, 1999.
29. **I. Melamed**, C.M. Roifman and E.W. Gelfand: A New Autosomal Recessive Skeletal Dysplasia with Immune Deficiency and Abnormal Vit. D Signaling, AAAI meeting, 1999.
30. **I. Melamed**: The Role of Signaling in Immunodeficiency, Israel, International Allergy meeting, 2000.
31. **I. Melamed**, J. Levy, S. Shatzky, R. Parvari and E.W. Gelfand: A Novel Immunodeficiency Trk A-Mutation in patients with Congenital Insensitivity to Pain and Anhidrosis (CIPA). FOCiS, San Francisco, 2002.
32. **I. Melamed**: Immunotherapy - How early is early? The American College of Allergy and Immunology, New Orleans, 2003.
33. **I. Melamed**: Parvovirus B-19 infection as a cause of severe ataxia in immunodeficient patient and the benefit of high dose IVIG. American College of Allergy and Immunology, New Orleans, 2003.

34. **I. Melamed**, B.G. Bender, M.Z. Wamboldt: The Benefit of Using Ceterizine (Zyrtec) With Stimulant in Children With Comorbid Allergy and ADHD, AAAI meeting, 2004.
35. A. Smith, F. Accurso, **I. Melamed**: Single Mutation in the Cystic Fibrosis Transmembrane Regulatory Gene in Patients With Chronic Sinusitis and Hypogammaglobulinemia: A Novel Immunodeficiency, AAAI meeting, 2004.
36. S.B. Beard, **I. Melamed**: The benefit of high-dose IVIG treatment in an immunocompromised patient who presented with idiopathic tremors, (submitted to AAAI, 2004).
37. J.A. Church, H. Leibl, M.R. Stein, **I. Melamed**, A. Rubinstein, et al. Efficacy, Safety and Tolerability of a New Intravenous Immune Globulin, 10% Liquid, Triple Virus Reduced (IGIV, 10%TVR) in Patients with Primary Immunodeficiency (PID). 05-A-1370-AAAI.
38. **I. Melamed**, A. McDonald, B. Jessen: Atopy as a Cause of Delayed Maturation of the Immune System. *Clinical Immunology* 2006; 119 (S): F.21.
39. **I. Melamed**, A. McDonald, M. Gonzalez: Autism as a Neuro-immune Disease-the Benefit Effect of IVIG. *Clinical Immunology* 2006; 119 (S): Sa. 46.
40. **I. Melamed**, S. Kelley, A. McDonald, D. Bar-Or: The Immunomodulatory Effect of IVIG in Parvovirus B-19 Induced Neuroimmune Disease. *Clinical Immunology* 2006; 119 (S): Sa. 45.
41. **I. Melamed**, A. Smith, F. Accurso: The Benefit of IVIG in Children with Chronic Sinus Disease Secondary to Single Mutation in the Cystic Fibrosis Transmembrane Regulatory Gene. *Clinical Immunology* 2006; 119 (S): Sa. 107.

